Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]JNJ-64511070 Brain Kinetics and Dosimetry in Healthy Men
NCT03270579Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]JNJ-64511070 in Alzheimer's disease (AD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Effective Radiation Dose Following Injection of [18F]JNJ-64511070 and Total and Regional Brain Compartmental Kinetics for Volume of Distribution of [18F]JNJ-64511070 in Brain at Day 1. Started Sep 2017; status: completed.
02
Drugs
[18F]JNJ-64511070
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03270579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03270579.